Glycozide 60mg Tablet MR contains gliclazide, a sulfonylurea class antidiabetic agent used in the management of type 2 diabetes mellitus. The modified-release (MR) formulation ensures a sustained release of the active ingredient, providing prolonged glycemic control with once-daily dosing. Gliclazide acts primarily by stimulating pancreatic beta cells to secrete insulin, thereby reducing blood glucose levels. It is indicated for patients with type 2 diabetes who have not achieved adequate glycemic control through diet and exercise alone. Glycozide 60mg MR should be used as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. The medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to sulfonylureas. Common side effects may include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy. Dose adjustments may be necessary based on glycemic response and tolerability. Glycozide 60mg Tablet MR offers an effective option for improving glycemic control in type 2 diabetes, thereby reducing the risk of long-term complications associated with hyperglycemia.